On the other hand, efforts should be made to either accelerate the development of safe and effective NF-κB–targeted therapies or repurpose existing clinically approved NF-κB inhibitors and explore their combination with current colitis treatments to improve the therapeutic effect for patients with periodontitis-mediated colitis. Here, NFKB1 is linked to colitis.